Corrigendum to "Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study" [Nutr Metab Cardiovasc Dis 19 (2009) 98-104] (DOI:10.1016/j.numecd.2008.04.001);Metabolic syndrome and left ventricular hypertrophy in the prediction of cardiovascular events: The Strong Heart Study

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 19, Issue 2, 2009, Pages 98-104

  de Simone, G ^a,b   Devereux, R B ^a   Chinali, M ^b   Roman, M J ^a   Lee, E T ^c   Resnick, H E ^d   Howard, B V ^d  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF OKLAHOMA   (United States)

^d MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

Diabetes; Hypertension; Obesity; Population attributable risk; Risk factors

Indexed keywords

EID: 60149089993     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.03.009     Document Type: Erratum

References (45)

1. WHO. Definition of metabolic syndrome in definition, diagnosis and classification of diabetes and its complications. Report of a WHO consultation. Part 1: Diagnosis and classification of diabetes mellitus (1999), World Health Organization - Department of Noncommunicable Disease Surveillance, Geneve WHO/NCD/NCS/99.2
2. Third Report of the National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106 (2002) 3143-3421
3. Balkau B., Charles M.A., Drivsholm T., Borch-Johnsen K., Wareham N., Yudkin J.S., et al. Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 28 (2002) 364-376
4. Einhorn D., Reaven G.M., Cobin R.H., Ford E., Ganda O.P., Handelsman Y., et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 9 (2003) 237-252
5. Alberti G. Introduction to the metabolic syndrome. Eur Heart J Suppl 7 (2005) 3-5
6. Lakka H.M., Laaksonen D.E., Lakka T.A., Niskanen L.K., Kumpusalo E., Tuomilehto J., et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 288 (2002) 2709-2716
7. Malik S., Wong N.D., Franklin S.S., Kamath T.V., L'Italien G.J., Pio J.R., et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110 (2004) 1245-1250
8. Schillaci G., Pirro M., Vaudo G., Gemelli F., Marchesi S., Porcellati C., et al. Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 43 (2004) 1817-1822
9. Grassi G., Quarti-Trevano F., Seravalle G., and Dell'Oro R. Cardiovascular risk and adrenergic overdrive in the metabolic syndrome. Nutr Metab Cardiovasc Dis 17 (2007) 473-481
10. Mule G., Cottone S., Mongiovi R., Cusimano P., Mezzatesta G., Seddio G., et al. Influence of the metabolic syndrome on aortic stiffness in never treated hypertensive patients. Nutr Metab Cardiovasc Dis 16 (2006) 54-59
11. Tartan Z., Ozer N., Uyarel H., Akgul O., Gul M., Cetin M., et al. Metabolic syndrome is a predictor for an ECG sign of no-reflow after primary PCI in patients with acute ST-elevation myocardial infarction. Nutr Metab Cardiovasc Dis (2007) [Epub ahead of print]
12. Gotto Jr. A.M., Blackburn G.L., Dailey III G.E., Garber A.J., Grundy S.M., Sobel B.E., et al. The metabolic syndrome: a call to action. Coron Artery Dis 17 (2006) 77-80
13. Grundy S.M., Brewer Jr. H.B., Cleeman J.I., Smith Jr. S.C., and Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 109 (2004) 433-438
14. Kahn R., Buse J., Ferrannini E., and Stern M. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 28 (2005) 2289-2304
15. Reilly M.P., and Rader D.J. The metabolic syndrome: more than the sum of its parts?. Circulation 108 (2003) 1546-1551
16. Devereux R.B., and Alderman M.H. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 88 (1993) 1444-1455
17. de Simone G., Devereux R.B., Chinali M., Best L.G., Lee E.T., Galloway J.M., et al. Prognostic impact of metabolic syndrome by different definitions in a population with high prevalence of obesity and diabetes: the Strong Heart Study. Diabetes Care 30 (2007) 1851-1856
18. de Simone G., Olsen M.H., Wachtell K., Hille D.A., Dahlof B., Ibsen H., et al. Clusters of metabolic risk factors predict cardiovascular events in hypertension with target-organ damage: the LIFE study. J Hum Hypertens 21 (2007) 625-632
19. Chinali M., Devereux R.B., Howard B.V., Roman M.J., Bella J.N., Liu J.E., et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 93 (2004) 40-44
20. Schillaci G., Pirro M., Vaudo G., Mannarino M.R., Savarese G., Pucci G., et al. Metabolic syndrome is associated with aortic stiffness in untreated essential hypertension. Hypertension 45 (2005) 1078-1082
21. Iannuzzi A., De Michele M., Bond M.G., Sacchetti L., Fortunato G., Salvatore F., et al. Carotid artery remodeling in middle-aged women with the metabolic syndrome (from the "Progetto ATENA" study). Am J Cardiol 96 (2005) 1162-1165
22. Lee E.T., Fabsitz R., Cowan L.D., Le N.A., Oopik A.J., Cucchiara A.J., et al. The Strong Heart Study - a study of cardiovascular disease in American Indians: design and methods. Am J Epidemiol 136 (1990) 1141-1155
23. Howard B.V., Lee E.T., Yeh J.L., Go O., Fabsitz R.R., Devereux R.B., et al. Hypertension in adult American Indians. The Strong Heart Study. Hypertension 28 (1996) 256-264
24. Welty T.K., Lee E.T., Yeh J., Cowan L.D., Go O., Fabsitz R.R., et al. Cardiovascular disease risk factors among American Indians. The Strong Heart Study. Am J Epidemiol 142 (1995) 269-287
25. Lee E.T., Cowan L.D., Welty T.K., Sievers M., Howard W.J., Oopik A., et al. All-cause mortality and cardiovascular disease mortality in three American Indian populations, aged 45-74 years, 1984-1988. The Strong Heart Study. Am J Epidemiol 147 (1998) 995-1008
26. Devereux R.B., Roman M.J., Paranicas M., O'Grady M.J., Lee E.T., Welty T.K., et al. Impact of diabetes on cardiac structure and function: the Strong Heart Study. Circulation 101 (2000) 2271-2276
27. Howard B.V., Lee E.T., Cowan L.D., Devereux R.B., Galloway J.M., Go O.T., et al. Rising tide of cardiovascular disease in American Indians. The Strong Heart Study. Circulation 99 (1999) 2389-2395
28. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-The Evidence Report. National Institutes of Health. Obes Res 6 (1998) 51S-209S
29. American Diabetes Association: clinical practice recommendations 1997. Diabetes Care 20 (1997) S1-S70
30. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., and Turner R.C. Homeostasis model assessment: insulin resistance and -cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28 (1985) 412-419
31. Devereux R.B., Alonso D.R., Lutas E.M., Gottlieb G.J., Campo E., Sachs I., et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol 57 (1986) 450-458
32. de Simone G., Daniels S.R., Devereux R.B., Meyer R.A., Roman M.J., de Divitiis O., et al. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and impact of overweight. J Am Coll Cardiol 20 (1992) 1251-1260
33. de Simone G., Kizer J.R., Chinali M., Roman M.J., Bella J.N., Best L.G., et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy The Strong Heart Study. Am J Hypertens 18 (2005) 191-196
34. de Simone G., Kizer J.R., Chinali M., Roman M.J., Bella J.N., Best L.G., et al. Normalization for body size and population-attributable risk of left ventricular hypertrophy: the Strong Heart Study. Am J Hypertens 18 (2005) 191-196
35. Dahlof B., Devereux R.B., de Faire U., Fyhrquist F., Hedner T., Ibsen H., et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension Study. Am J Hypertens 10 (1997) 705-713
36. Mancia G., Bombelli M., Corrao G., Facchetti R., Madotto F., Giannattasio C., et al. Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: daily life blood pressure, cardiac damage, and prognosis. Hypertension 49 (2007) 40-47
37. Cuspidi C., Meani S., Fusi V., Severgnini B., Valerio C., Catini E., et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 22 (2004) 1991-1998
38. Leoncini G., Ratto E., Viazzi F., Vaccaro V., Parodi D., Parodi A., et al. Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 257 (2005) 454-460
39. Burchfiel C.M., Skelton T.N., Andrew M.E., Garrison R.J., Arnett D.K., Jones D.W., et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 112 (2005) 819-827
40. Cuspidi C., Meani S., Valerio C., Sala C., Fusi V., Zanchetti A., et al. Age and target organ damage in essential hypertension: role of the metabolic syndrome. Am J Hypertens 20 (2007) 296-303
41. Davis C.L., Kapuku G., Snieder H., Kumar M., and Treiber F.A. Insulin resistance syndrome and left ventricular mass in healthy young people. Am J Med Sci 324 (2002) 72-75
42. Suman O.E., Hasten D., Turner M.J., Rinder M.R., Spina R.J., and Ehsani A.A. Enhanced inotropic response to dobutamine in strength-trained subjects with left ventricular hypertrophy. J Appl Physiol 88 (2000) 534-539
43. Laclaustra M., Corella D., and Ordovas J.M. Metabolic syndrome pathophysiology: the role of adipose tissue. Nutr Metab Cardiovasc Dis 17 (2007) 125-139
44. Devereux R.B., Roman M.J., Liu J.E., Lee E.T., Wang W., Fabsitz R.R., et al. An appraisal of echocardiography as an epidemiological tool. The Strong Heart Study. Ann Epidemiol 13 (2003) 238-244
45. Giampaoli S., Palmieri L., Mattiello A., and Panico S. Definition of high risk individuals to optimise strategies for primary prevention of cardiovascular diseases. Nutr Metab Cardiovasc Dis 15 (2005) 79-85